Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Jane Street Group LLC

Jane Street Group LLC reduced its stake in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 56.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 89,800 shares of the company’s stock after selling 114,237 shares during the period. Jane Street Group LLC’s holdings in Acelyrin were worth $443,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in SLRN. Principal Financial Group Inc. acquired a new stake in Acelyrin during the second quarter worth about $49,000. HighTower Advisors LLC acquired a new stake in shares of Acelyrin during the 3rd quarter worth about $50,000. Intech Investment Management LLC purchased a new position in Acelyrin during the third quarter worth about $77,000. US Bancorp DE increased its position in shares of Acelyrin by 77.1% during the third quarter. US Bancorp DE now owns 16,854 shares of the company’s stock valued at $83,000 after acquiring an additional 7,336 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Acelyrin by 65.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,196 shares of the company’s stock valued at $95,000 after acquiring an additional 7,560 shares during the last quarter. Institutional investors and hedge funds own 87.31% of the company’s stock.

Wall Street Analysts Forecast Growth

SLRN has been the subject of a number of research reports. HC Wainwright reaffirmed a “neutral” rating and issued a $8.00 price objective on shares of Acelyrin in a research note on Wednesday, December 11th. Wells Fargo & Company cut their price target on Acelyrin from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th.

Acelyrin Trading Down 8.6 %

Shares of NASDAQ:SLRN opened at $3.49 on Tuesday. Acelyrin, Inc. has a 52 week low of $3.05 and a 52 week high of $8.89. The company’s 50 day moving average is $4.45 and its two-hundred day moving average is $4.90. The company has a market cap of $350.14 million, a PE ratio of -1.42 and a beta of 1.94.

Acelyrin Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.